Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI.

Jack CR Jr, Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, Knopman DS, Smith GE, Ivnik RJ, Tangalos EG, Petersen RC.

Neurology. 2005 Oct 25;65(8):1227-31.

2.

Longitudinal volumetric MRI change and rate of cognitive decline.

Mungas D, Harvey D, Reed BR, Jagust WJ, DeCarli C, Beckett L, Mack WJ, Kramer JH, Weiner MW, Schuff N, Chui HC.

Neurology. 2005 Aug 23;65(4):565-71.

3.

Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment.

Fleisher A, Grundman M, Jack CR Jr, Petersen RC, Taylor C, Kim HT, Schiller DH, Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study.

Arch Neurol. 2005 Jun;62(6):953-7.

PMID:
15956166
4.

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M; AN1792(QS-21)-201 Study.

Neurology. 2005 May 10;64(9):1563-72.

PMID:
15883317
5.

Vitamin E and donepezil for the treatment of mild cognitive impairment.

Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study Group.

N Engl J Med. 2005 Jun 9;352(23):2379-88. Epub 2005 Apr 13.

6.

Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?

Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E.

Am J Psychiatry. 2005 Apr;162(4):676-82.

PMID:
15800138
7.

Impact of APOE in mild cognitive impairment.

Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC.

Neurology. 2004 Nov 23;63(10):1898-901.

PMID:
15557508
8.

Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia.

DeCarli C, Mungas D, Harvey D, Reed B, Weiner M, Chui H, Jagust W.

Neurology. 2004 Jul 27;63(2):220-7.

9.

Predicting the rate of cognitive decline in aging and early Alzheimer disease.

Adak S, Illouz K, Gorman W, Tandon R, Zimmerman EA, Guariglia R, Moore MM, Kaye JA.

Neurology. 2004 Jul 13;63(1):108-14.

PMID:
15249619
10.

Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.

Jack CR Jr, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, Tangalos EG, Petersen RC.

Neurology. 2004 Feb 24;62(4):591-600.

11.

Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.

Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR Jr, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ; Alzheimer's Disease Cooperative Study.

Arch Neurol. 2004 Jan;61(1):59-66.

PMID:
14732621
12.

Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.

Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S.

Am J Psychiatry. 2003 Nov;160(11):2003-11.

PMID:
14594748
13.

Methodological considerations for measuring rates of brain atrophy.

Gunter JL, Shiung MM, Manduca A, Jack CR Jr.

J Magn Reson Imaging. 2003 Jul;18(1):16-24.

14.

Atrophy rates of entorhinal cortex in AD and normal aging.

Du AT, Schuff N, Zhu XP, Jagust WJ, Miller BL, Reed BR, Kramer JH, Mungas D, Yaffe K, Chui HC, Weiner MW.

Neurology. 2003 Feb 11;60(3):481-6.

15.

MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD.

Jack CR Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, Xu Y, Shiung M, O'Brien PC, Cha R, Knopman D, Petersen RC.

Neurology. 2003 Jan 28;60(2):253-60.

16.

Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes.

den Heijer T, Oudkerk M, Launer LJ, van Duijn CM, Hofman A, Breteler MM.

Neurology. 2002 Sep 10;59(5):746-8.

PMID:
12221169
17.

MRI measures of entorhinal cortex vs hippocampus in preclinical AD.

Killiany RJ, Hyman BT, Gomez-Isla T, Moss MB, Kikinis R, Jolesz F, Tanzi R, Jones K, Albert MS.

Neurology. 2002 Apr 23;58(8):1188-96.

PMID:
11971085
18.

MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease.

Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Bennett DA, Beckett LA, deToledo-Morrell L.

Neurobiol Aging. 2001 Sep-Oct;22(5):747-54.

PMID:
11705634
19.

Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.

Jack CR Jr, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Tangalos EG, Kokmen E.

Neurology. 2000 Aug 22;55(4):484-89.

20.

Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.

Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman BT, Albert MS.

Ann Neurol. 2000 Apr;47(4):430-9.

PMID:
10762153

Supplemental Content

Support Center